# A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Pl

Source: https://onco.cc/trials/nct03246529/  
OnCo record `nct03246529` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Filgrastim in multiple myeloma, run by BioLineRx, Ltd., active and no longer recruiting.

## Summary

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) is a phase 3 interventional study registered as NCT03246529 by BioLineRx, Ltd., with 180 participants enrolled, started 2018-03-23 and due to reach its primary completion in 2020-12-22. Interventions recorded: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03246529
- Phase: 3
- Setting: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study
- Sponsor: BioLineRx, Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT03246529: https://clinicaltrials.gov/study/NCT03246529

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/)
- companies: [BioLineRx](https://onco.cc/companies/biolinerx/)

---
JSON: https://onco.cc/api/v1/entities/nct03246529.json